MetLife, Inc. (NYSE:MET) Given Consensus Rating of "Moderate Buy" by Analysts

Market Beat
2024.09.25 06:51
portai
I'm PortAI, I can summarize articles.

MetLife, Inc. (NYSE:MET) has received a consensus rating of "Moderate Buy" from thirteen analysts. One analyst rated it as hold, while twelve rated it as buy. The average 1-year target price is $54. Recent reports show mixed price target adjustments from various firms. Institutional investors hold 89.81% of the stock. MetLife's stock opened at $45.45, with a market cap of $54.21 billion. The company reported earnings of $1.28 per share, exceeding estimates, and announced a quarterly dividend of $0.545, yielding 2.71%.

MetLife, Inc. (NYSE:MET - Get Free Report) has received a consensus rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $84.54.

  • 2 Insurance Stocks Poised For Major Breakouts

MET has been the topic of several research reports. Morgan Stanley dropped their price objective on shares of MetLife from $86.00 to $85.00 and set an "overweight" rating on the stock in a report on Monday, August 19th. Jefferies Financial Group upped their price target on MetLife from $83.00 to $86.00 and gave the stock a "buy" rating in a research note on Thursday, July 18th. Bank of America reduced their price objective on MetLife from $99.00 to $96.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. StockNews.com downgraded MetLife from a "buy" rating to a "hold" rating in a report on Tuesday, September 10th. Finally, Citigroup increased their target price on MetLife from $83.00 to $89.00 and gave the stock a "buy" rating in a report on Tuesday, July 23rd.

View Our Latest Report on MetLife

Institutional Trading of MetLife

  • MarketBeat Week in Review – 8/21 - 8/25

A number of institutional investors and hedge funds have recently modified their holdings of MET. Gilbert & Cook Inc. increased its position in shares of MetLife by 4.6% during the 4th quarter. Gilbert & Cook Inc. now owns 13,872 shares of the financial services provider's stock valued at $917,000 after purchasing an additional 605 shares during the last quarter. Gryphon Financial Partners LLC purchased a new stake in MetLife during the fourth quarter worth about $201,000. Cambridge Investment Research Advisors Inc. raised its position in MetLife by 7.8% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 78,499 shares of the financial services provider's stock worth $5,191,000 after acquiring an additional 5,707 shares during the period. US Bancorp DE boosted its stake in MetLife by 1.3% in the fourth quarter. US Bancorp DE now owns 106,391 shares of the financial services provider's stock valued at $7,036,000 after acquiring an additional 1,340 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. grew its position in shares of MetLife by 0.4% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 185,735 shares of the financial services provider's stock valued at $12,283,000 after acquiring an additional 816 shares during the period. 89.81% of the stock is owned by hedge funds and other institutional investors.

MetLife Stock Down 1.2 %

Shares of MetLife stock opened at $80.45 on Wednesday. The stock's 50-day moving average is $74.90 and its 200 day moving average is $72.78. MetLife has a one year low of $57.91 and a one year high of $81.85. The firm has a market cap of $57.21 billion, a price-to-earnings ratio of 27.65, a PEG ratio of 0.61 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.16 and a quick ratio of 0.16.


  • This Insurance Giant Looks Ready For A Breakout

MetLife (NYSE:MET - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The financial services provider reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.15. The company had revenue of $17.82 billion during the quarter, compared to analyst estimates of $18.57 billion. MetLife had a net margin of 4.23% and a return on equity of 21.41%. MetLife's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.94 EPS. Equities research analysts anticipate that MetLife will post 8.67 EPS for the current year.

MetLife Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 6th were paid a $0.545 dividend. The ex-dividend date of this dividend was Tuesday, August 6th. This represents a $2.18 dividend on an annualized basis and a dividend yield of 2.71%. MetLife's payout ratio is presently 74.91%.

About MetLife

(Get Free Report

MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.

See Also

  • Five stocks we like better than MetLife
  • Where to Find Earnings Call Transcripts
  • Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
  • 3 Healthcare Dividend Stocks to Buy
  • Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
  • What is Insider Trading? What You Can Learn from Insider Trading
  • Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ CNBC’s ‘Prophet’ issues urgent Fed warning (From Stansberry Research) (Ad)

Should you invest $1,000 in MetLife right now?

Before you consider MetLife, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.

While MetLife currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here